Daraxonrasib nearly doubles survival in previously treated metastatic pancreatic cancer
Published on 31 May 2026
Dr Brian Wolpin talks to ecancer at ASCO 2026 about results from the phase 3 RASolute 302 trial evaluating daraxonrasib as second-line treatment for metastatic pancreatic ductal adenocarcinoma.
The RAS(ON) multi-selective inhibitor nearly doubled overall survival and improved progression-free survival and response rates compared with chemotherapy, with fewer serious side effects.
Dr Wolpin notes that daraxonrasib has potential as anew standard of care in the second-line setting for metastatic pancreatic cancer.
Read the news story here.
This information is intended for health care professionals only. The information is not intended for US health care professionals.